Eylea

Novartis knocked by safety scare
Novartis knocked by safety scare
EP Vantage
Novartis
Regeneron
Beovu
Eylea
wet age-related macular degeneration
Flag link:
Regeneron’s Eylea delivers positive two-year results in PANORAMA trial
Regeneron’s Eylea delivers positive two-year results in PANORAMA trial
Pharmaceutical Business Review
Regeneron
Eylea
diabetic neuropathy
NPDR
clinical trials
Flag link:
Are Novartis and Regeneron seeing the same thing?
Are Novartis and Regeneron seeing the same thing?
BioPharma Dive
Novartis
Regeneron
physicians
Eylea
Beovu
Flag link:
Biogen signs marketing deal for two ophthalmology biosimilars
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Flag link:
Regeneron profit beats expectations on Eylea, Dupixent strength
Regeneron profit beats expectations on Eylea, Dupixent strength
Yahoo/Reuters
Regeneron
earnings
Eylea
Dupixent
Flag link:
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Biopharma Dive
Regeneron
M&A
Eylea
Flag link:
Eylea casts a shadow over Novartis' latest approval
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Flag link:
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Pharmaforum
Novartis
brolucizumab
Bayer
Eylea
wet age-related macular degeneration
FDA
Flag link:
Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
Flag link:
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
Regeneron gets FDA approval for Eylea injection prefilled syringe
Regeneron gets FDA approval for Eylea injection prefilled syringe
Ophthalmology Times
Regeneron
Eylea
FDA
Flag link:
FDA approves Regeneron’s Eylea for diabetic retinopathy
FDA approves Regeneron’s Eylea for diabetic retinopathy
Pharmaforum
Regeneron
Eylea
diabetic retinopathy
FDA
Bayer
Flag link:
With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap?
With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap?
Fierce Pharma
Bayer
Xarelto
Eylea
Flag link:
Regeneron touts one-year diabetic retinopathy data for Eylea
Regeneron touts one-year diabetic retinopathy data for Eylea
Drug Delivery Business News
Regeneron
Eylea
proliferative diabetic retinopathy
Flag link:
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
Flag link:
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
Flag link:
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
Endpoints
Regeneron
FDA
Eylea
complete response letter
Flag link:
FDA to review Regeneron’s Eylea for diabetic retinopathy
FDA to review Regeneron’s Eylea for diabetic retinopathy
Drug Delivery Business News
Regeneron
FDA
Eylea
diabetic retinopathy
Flag link:

Pages